Approval · Notice of Compliance 37993 · 2026
NAT-PALBOCICLIB: Notice of Compliance 37993
Issued July 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37993
- Date
- July 27, 2026
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- IBRANCE (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-PALBOCICLIB | 02570130 | Approved |
| NAT-PALBOCICLIB | 02570149 | Approved |
| NAT-PALBOCICLIB | 02570157 | Approved |
Medicinal ingredients
- PALBOCICLIB 75 MG per TAB
- PALBOCICLIB 100 MG per TAB
- PALBOCICLIB 125 MG per TAB